Treatment of Cutaneous Melanoma

Mary Ann N Johnson; April W. Armstrong

doi:10.1002/9781118357606.ch31

Treatment of Cutaneous Melanoma

Mary Ann N Johnson, April W. Armstrong

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

This chapter briefly discusses the primary cutaneous melanoma and its incidence, risk factors, diagnosis, prognosis and treatment objectives. It also describes the recommendations for surgical excision margins based on the Breslow thickness of the melanoma. The management of patients with lentigo maligna (LM) or lentigo maligna melanoma (LMM), and the role of sentinel lymph-node biopsy are discussed in detail. The chapter also discusses the therapies to improve overall survival in patients with metastatic malignant melanoma. It also discusses the question: Does antisense therapy against B-cell lymphoma 2 improve outcomes in patients with metastatic melanoma. Developments in the systemic treatment of melanoma have resulted in improved survival for advance metastatic melanoma (Stage IV). The role of cytotoxic chemotherapeutic agents, as monotherapy and in combination regimens, is limited in initial treatment for metastatic melanoma.

Original language	English (US)
Title of host publication	Evidence-Based Dermatology: Third Edition
Publisher	Wiley Blackwell
Pages	231-240
Number of pages	10
ISBN (Print)	9781118357606, 9781118357675
DOIs	https://doi.org/10.1002/9781118357606.ch31
State	Published - Aug 11 2014
Externally published	Yes

Keywords

Antisense therapy
Cytotoxic chemotherapeutic agents
Lentigo maligna melanoma (LMM)
Metastatic malignant melanoma
Primary cutaneous melanoma
Sentinel lymph-node biopsy

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1002/9781118357606.ch31

Cite this

@inbook{97d230ba15304c5fa11a3e2d46f7d104,

title = "Treatment of Cutaneous Melanoma",

abstract = "This chapter briefly discusses the primary cutaneous melanoma and its incidence, risk factors, diagnosis, prognosis and treatment objectives. It also describes the recommendations for surgical excision margins based on the Breslow thickness of the melanoma. The management of patients with lentigo maligna (LM) or lentigo maligna melanoma (LMM), and the role of sentinel lymph-node biopsy are discussed in detail. The chapter also discusses the therapies to improve overall survival in patients with metastatic malignant melanoma. It also discusses the question: Does antisense therapy against B-cell lymphoma 2 improve outcomes in patients with metastatic melanoma. Developments in the systemic treatment of melanoma have resulted in improved survival for advance metastatic melanoma (Stage IV). The role of cytotoxic chemotherapeutic agents, as monotherapy and in combination regimens, is limited in initial treatment for metastatic melanoma.",

keywords = "Antisense therapy, Cytotoxic chemotherapeutic agents, Lentigo maligna melanoma (LMM), Metastatic malignant melanoma, Primary cutaneous melanoma, Sentinel lymph-node biopsy",

author = "Johnson, {Mary Ann N} and Armstrong, {April W.}",

year = "2014",

month = aug,

day = "11",

doi = "10.1002/9781118357606.ch31",

language = "English (US)",

isbn = "9781118357606",

pages = "231--240",

booktitle = "Evidence-Based Dermatology: Third Edition",

publisher = "Wiley Blackwell",

}

TY - CHAP

T1 - Treatment of Cutaneous Melanoma

AU - Johnson, Mary Ann N

AU - Armstrong, April W.

PY - 2014/8/11

Y1 - 2014/8/11

N2 - This chapter briefly discusses the primary cutaneous melanoma and its incidence, risk factors, diagnosis, prognosis and treatment objectives. It also describes the recommendations for surgical excision margins based on the Breslow thickness of the melanoma. The management of patients with lentigo maligna (LM) or lentigo maligna melanoma (LMM), and the role of sentinel lymph-node biopsy are discussed in detail. The chapter also discusses the therapies to improve overall survival in patients with metastatic malignant melanoma. It also discusses the question: Does antisense therapy against B-cell lymphoma 2 improve outcomes in patients with metastatic melanoma. Developments in the systemic treatment of melanoma have resulted in improved survival for advance metastatic melanoma (Stage IV). The role of cytotoxic chemotherapeutic agents, as monotherapy and in combination regimens, is limited in initial treatment for metastatic melanoma.

AB - This chapter briefly discusses the primary cutaneous melanoma and its incidence, risk factors, diagnosis, prognosis and treatment objectives. It also describes the recommendations for surgical excision margins based on the Breslow thickness of the melanoma. The management of patients with lentigo maligna (LM) or lentigo maligna melanoma (LMM), and the role of sentinel lymph-node biopsy are discussed in detail. The chapter also discusses the therapies to improve overall survival in patients with metastatic malignant melanoma. It also discusses the question: Does antisense therapy against B-cell lymphoma 2 improve outcomes in patients with metastatic melanoma. Developments in the systemic treatment of melanoma have resulted in improved survival for advance metastatic melanoma (Stage IV). The role of cytotoxic chemotherapeutic agents, as monotherapy and in combination regimens, is limited in initial treatment for metastatic melanoma.

KW - Antisense therapy

KW - Cytotoxic chemotherapeutic agents

KW - Lentigo maligna melanoma (LMM)

KW - Metastatic malignant melanoma

KW - Primary cutaneous melanoma

KW - Sentinel lymph-node biopsy

UR - http://www.scopus.com/inward/record.url?scp=84926400451&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926400451&partnerID=8YFLogxK

U2 - 10.1002/9781118357606.ch31

DO - 10.1002/9781118357606.ch31

M3 - Chapter

AN - SCOPUS:84926400451

SN - 9781118357606

SN - 9781118357675

SP - 231

EP - 240

BT - Evidence-Based Dermatology: Third Edition

PB - Wiley Blackwell

ER -

Treatment of Cutaneous Melanoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this